3 days popular7 days popular1 month popular3 months popular

Bavarian Nordic announces initiation of NCI-sponsored phase 2 study of PROSVAC in patients with localized prostate cancer

A/S has announced that the first patient has been enrolled in a new phase 2 clinical study of PROSTVAC, the Company’s active immunotherapy candidate. The study is designed as a randomized, double-blind, placebo-controlled study for men who have localized , and are undergoing active surveillance. These patients are not experiencing symptoms related to their cancer, and are not being treated with other therapies. The study is sponsored by the National Cancer Institute (NCI) as part of a Collaborative Research and Development Agreement (CRADA) and Clinical Supply Agreement between and the NCI.

The study will be conducted across 6 sites, and is designed to enroll 90 patients with the potential to expand up to 150 patients. The primary endpoint of the study is to determine how well PROSTVAC works in eliciting an immune response in patients with prostate cancer that is found only in the prostate and has not yet metastasized. Changes in CD8 and CD4 T cells in tissue adjacent to the tumor and within malignant portion of prostate biopsies will be measured as will changes in PSA. Secondary endpoints include effects of PROSTVAC on changes in PD-L1 expression, PSA doubling time, and change in tumor grade (Gleason score). The principal investigator of the study is J. Kellogg Parsons, M.D., MHS, University of California San Diego. More information on the trial can be found at http://www.clinicaltrials.gov/ct2/show/NCT02326805.

“This is a wonderful opportunity to explore the potential benefits of using an active immunotherapy on patients in the early disease setting. It is widely believed that using immunotherapy with patients who have a lower disease burden might benefit even more than the efficacy we have already seen in the later stage settings of prostate cancer, thus providing a larger commercial potential for the product candidate. We thank the NCI, and our clinical collaborators, for initiating this study, and look forward to following its progress,” said Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic.

About PROSTVAC

PROSTVAC is a ready to use immuno-oncology agent that stimulates an immune response that attacks prostate cancer cells. Administered subcutaneously, PROSTVAC employs Bavarian Nordic’s active immunotherapy (vaccinia-fowlpox/TRICOM) technology platform. When PSA-TRICOM is presented to the immune system in the PROSTVAC regimen, cytotoxic T lymphocytes (CTLs) are generated that may recognize and kill PSA-expressing cancer cells and trigger an immune response to other tumor antigens. PROSTVAC is currently being evaluated in a global, randomized, double-blind, placebo-controlled phase 3 study (PROSPECT), that has fully enrolled at 1,298 patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Previous clinical studies of PROSTVAC, either as single-agent therapy or in combination with anti-androgen therapies, radiation therapies or immune checkpoint inhibitors have indicated possible therapeutic synergies for these treatment combinations and PROSTVAC has been generally well-tolerated.

Source

Source: Bavarian Nordic